Home - IDDRIVE

id.DRIVE open partnership

An open public-private partnership to facilitate the conduct of observational studies on infectious diseases, related vaccines, preventive measures, therapeutics and diagnostics.

Interested in important updates on the partnership?
Subscribe to our newsletter by contacting us

Newsflash

WHAT IS id.DRIVE?

id.DRIVE is a privately funded not-for-profit open public-private partnership that facilitates the conduct of observational and low interventional studies on infectious diseases and related vaccines, preventive measures, therapeutics and diagnostics. These studies support public health responses globally and address pharmaceutical companies’ regulatory obligations. This multi-stakeholder partnership brings together public institutions, small and medium sized enterprises (SMEs) and pharmaceutical companies. As an open partnership, id.DRIVE welcomes new partners and study contributors (sites) anytime.

id.DRIVE was launched in 2024 as the successor of COVIDRIVE, a public-private partnership that was set up in 2021 amidst the COVID-19 pandemic to perform COVID-19 Vaccine Effectiveness studies. COVIDRIVE rooted in from the European Commission Innovative Medicines Initiative (IMI)-funded DRIVE consortium for Influenza Vaccine Effectiveness evaluation in Europe (2017-2022). id.DRIVE expands the scope of COVIDRIVE beyond COVID-19 and runs several studies across different respiratory infectious diseases, with a focus on surveillance and vaccine effectiveness.

VISION AND MISSION

JOINING FORCES TOWARDS A BETTER UNDERSTANDING AND PREVENTION OF INFECTIOUS DISEASES, VACCINES AND THERAPEUTICS

To jointly develop methodological and technical resources to undertake infectious diseases studies in Europe.

To conduct large scale multi-centre observational studies.

To leverage established public health capacities and optimize health care professional resources in large data collections supporting multiple studies.

To build a sustainable partnership by establishing and maintaining a rich scientific community, central data sharing and analysis platform, supporting study documents and regulatory communication.

Scope

This open partnership conducts studies on infectious diseases, related vaccines, preventive measures, therapeutics and diagnostics. The studies fall under the following scope:

– Burden of disease, including impact on health care utilisation.

– Effectiveness of vaccines, related preventive measures, therapeutics and diagnostics for infectious diseases.

– Impact of vaccination and related infectious diseases prevention programs and therapeutics treatments.

– Safety studies of vaccines, related preventive measures, therapeutics, and diagnostics for infectious diseases..